Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Shandong Keyuan Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:
SZSE:301281'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.07 Max: 0.33
Current: 0.14
During the past 13 years, the highest Debt-to-Equity Ratio of Shandong Keyuan Pharmaceutical Co was 0.33. The lowest was 0.02. And the median was 0.07.
SZSE:301281's Debt-to-Equity is ranked better than 67.2% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs SZSE:301281: 0.14
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Shandong Keyuan Pharmaceutical Co Debt-to-Equity Related Terms
Shandong Keyuan Pharmaceutical Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Keyuan Pharmaceutical Co Debt-to-Equity Chart
SZSE:301281 vs LLY, JNJ, ABBV: Debt-to-Equity Comparison
For the Drug Manufacturers - General subindustry, Shandong Keyuan Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Keyuan Pharmaceutical Co Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shandong Keyuan Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Shandong Keyuan Pharmaceutical Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Keyuan Pharmaceutical Co (SZSE:301281) has a Debt-to-Equity of 0.14 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Shandong Keyuan Pharmaceutical Co and its competitors. This is 100% above median its historical median of 0.07. Over the past decade, Shandong Keyuan Pharmaceutical Co's Debt-to-Equity has ranged from 0.02 to 0.33. According to the industry distribution chart, Shandong Keyuan Pharmaceutical Co ranks #266 out of 811 companies in the Drug Manufacturers industry, placing it in the top 32.8%.
Is Shandong Keyuan Pharmaceutical Co's Debt-to-Equity too high?
Shandong Keyuan Pharmaceutical Co's current Debt-to-Equity of 0.14 is 100% above median its 10-year median of 0.07. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.33. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Shandong Keyuan Pharmaceutical Co's value of 0.14 is 50% below this industry median. Based on the distribution chart, Shandong Keyuan Pharmaceutical Co ranks #266 out of 811 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shandong Keyuan Pharmaceutical Co has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Keyuan Pharmaceutical Co's Debt-to-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Shandong Keyuan Pharmaceutical Co ranks #266 out of 811 companies for Debt-to-Equity. This puts Shandong Keyuan Pharmaceutical Co in the upper half of its industry. The industry median Debt-to-Equity is 0.28. Shandong Keyuan Pharmaceutical Co's value of 0.14 is 50% below this benchmark. Historically, Shandong Keyuan Pharmaceutical Co's own Debt-to-Equity has ranged from 0.02 to 0.33 over the past decade. While the company's 10-year median is 0.07 vs. the industry median of 0.28, Shandong Keyuan Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Keyuan Pharmaceutical Co's current Debt-to-Equity of 0.14 is 50% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Shandong Keyuan Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Keyuan Pharmaceutical Co's current Debt-to-Equity is 0.14, which is 100% above median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Keyuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Keyuan Pharmaceutical Co (SZSE:301281) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥33.98, compared to a current price of ¥48.95 — trading 44.1% above its estimated fair value. The current Debt-to-Equity is 0.14, which is 100% above median its 10-year median of 0.07 and 50% below the Drug Manufacturers industry median of 0.28. Shandong Keyuan Pharmaceutical Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Shandong Keyuan Pharmaceutical Co (SZSE:301281), the current Debt-to-Equity is 0.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Keyuan Pharmaceutical Co (SZSE:301281) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Keyuan Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥48.95 is trading 44.1% above its estimated GF Value™ of ¥33.98.
GuruFocus considers Shandong Keyuan Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SZSE:301281:
Debt-to-Equity: 0.14 (100% above median its 10-year median of 0.07)
GF Value™: ¥33.98 vs. price of ¥48.95 (44.1% above fair value)
Industry Position: 50% below the Drug Manufacturers median (#266 of 811)
No single metric tells the full story. See the SZSE:301281 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Keyuan Pharmaceutical Co Ltd is engaged in the research and development, production, and sales of chemical raw materials and their preparations.
74GF Score
Get the complete analysis for SZSE:301281
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301281 has been successfully added to your 
